Pengfei Tu

Professor & Director of Department of Natural Medicines

Research Areas

Chemistry & Chemical Biology of Natural Medicines.

University of Science and Technology of China (USTC), B.S., 1994.

Massachusetts Institute of Technology, Ph.D., 2000.

Education & Positions

Nanjing College of Pharmacy, B.S., 1981-1985.

China Pharmaceutical University, Ph.D., 1985-1990.

Toyama Medical and Pharmaceutical University (Japan), Ph.D.student, 1988-1989.

Beijing Medical University, Postdoctoral Fellow, 1990-1992, Associated Professor 1993-1997, Professor 1997-2000.

Peking University, Professor, 2000.5-Present.

11st Executive Member and Chairman of Specialized Committee for Chinese Medicinal Materials, Chinese Pharmacopoeia Committee.

Associate Chief-Editors of Tradit Chin Drug Res Clin Pharmacol, J Chin Pharma Sci and Modern Chin Med.

Editors of J Chromatogr B, J Asian Nat Prod Res,Chin J Nat Med, Chin Tradit Herb Drugs, Chin J Mater Med, J Chin Pharma Univ, and Chin J Exp Tradit Med Form.

Faculty Accolades

Second Class Prize of the National Science and Technology Progress Award of China, 2015.

First Class Prize of the Science and Technology Award of China Association of Chinese Medicine, 2017.

First Class Prize of the Scientific and Technological Progress Award of Ministry of Education of China, 2016.

First Class Prize of the Scientific and Technological Progress Award of Ministry of Education of China, 2008.

First Class Prize of the Natural Science Award of Ministry of Education of China, 2004.

Research Interests

My researches focus on two aspects: discovery of active components from natural medicines and their action mechanism; quality control of traditional Chinese medicines. The chemical components of traditional Chinese medicines, ethnodrugs and folk medicines are isolated and identified by various chromatographic and spectroscopic methods. Then, the isolated components are screenedin vitro and in vivo for finding their specific activities. Pharmacological and chemical biological methods are carried to study the targets of those active molecules and their molecular mechanism. By using these methods, the active ingredients of traditional Chinese medicines and their medicinal mechanisms are clarified. Then, the active components with potential clinical values are developed into innovative drugs. Meanwhile, our laboratory uses HPLC, LC-MS and other technologies to establish efficient analytical methods for complex traditional Chinese medicines and realize their overall quality control.  

Grants and fundings

Natural Science Foundation of China (NSFC, Nos. 81773832,81530097, 81373294).

National Key Technology R&D Program “New Drug Innovation” of China (Nos. 2017ZX09101003-008-003, 2013ZX09508-105, 2012ZX09304005-001).

National Science and Technology Projects for the Benefit of the People (No. 2012GS650101).

Publications  

1. Liao LX, Song XM, Wang LC, Lv HN, Chen JF, Liu D, Fu G, Zhao MB, Jiang Y, Zeng KW*, Tu PF*. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflam- mation therapy. PNAS. 2017, 1706778114. (IF = 9.661)

2. Wang J, Wang XH, Liu X, Li J, Shi XP, Song YL, Zeng KW, Zhang L, Tu PF*, Shi SP*. Synthesis of unnatural 2-substituted quinolones and 1,3-diketones by a member of type III polyketide synthases from Huperzia serrata. Org. Lett. 2016, 18, 3550-3. (IF = 6.579)

3. Ai XN, Lu WB, Zeng KW, Li C, Jiang Y*, Tu PF*. Microfluidic coculture device for monitoring of inflammation induced myocardial injury dynamics. Anal. Chem. 2018, 90, 4485-94. (IF = 6.320)

4. Song YL, Song QQ, Liu Y, Li J, Wan JB, Wang YT, Jiang Y*, Tu PF*. Integrated work-flow for quantitative metabolome profiling of plants, Peucedani Radix as a case. Anal. Chim. Acta. 2017, 953, 40-7. (IF = 5.123)

5.  Zhang C, Wang S, Zeng KW, Li J, Ferreira D, Zjawiony JK, Liu BY, Guo XY, Jin HW, Jiang Y*, Tu PF*. Nitric oxide inhibitory dimeric sesquiterpenoids from Artemisia rupestris. J. Nat. Prod. 2016, 79, 213-23. (IF = 3.662)